Mesothelioma and Asbestos

Researchers at the Stony Brook University Cancer Center in Stony Brook, New York announced that recent findings of meta-analysis support clinical trial data regarding increased risk of kidney damage when mesothelioma as well as other cancer patients using chemotherapy are as well as given Avastin. Adding Avastin to the cancer therapy program that includes chemotherapy more than quadruples the risk of kidney disease compared to chemotherapy alone. Nephrotic syndrome risk was as well as dramatically increased. Nephrotic syndrome is a collection of symptoms including excess protein in the urine, abridged protein levels in the blood, high cholesterol as well as triglyceride levels as well as edema.

The study examined data from several dissimilar clinical trials involving 12,268 patients with dissimilar types of cancers. At most risk were patients with renal cell carcinoma as well as those using high doses of Avastin. Patients at lowest risk had tiny cell lung cancer. The research group advises lower dosage as well as careful monitoring of Avastin/chemotherapy patients to minimize the risk of kidney disease.

For the filled story, go to Med Page Today.